ATE340786T1 - Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel - Google Patents

Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel

Info

Publication number
ATE340786T1
ATE340786T1 AT01982663T AT01982663T ATE340786T1 AT E340786 T1 ATE340786 T1 AT E340786T1 AT 01982663 T AT01982663 T AT 01982663T AT 01982663 T AT01982663 T AT 01982663T AT E340786 T1 ATE340786 T1 AT E340786T1
Authority
AT
Austria
Prior art keywords
salts
isothiazole carboxamide
hyperproliferation agents
hyperproliferation
agents
Prior art date
Application number
AT01982663T
Other languages
English (en)
Inventor
Thomas G Gant
Glenn Robert Williams
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE340786T1 publication Critical patent/ATE340786T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT01982663T 2000-11-28 2001-11-19 Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel ATE340786T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28

Publications (1)

Publication Number Publication Date
ATE340786T1 true ATE340786T1 (de) 2006-10-15

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982663T ATE340786T1 (de) 2000-11-28 2001-11-19 Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel

Country Status (49)

Country Link
US (1) US6831091B2 (de)
EP (1) EP1337521B1 (de)
JP (2) JP2004514714A (de)
KR (2) KR20050116401A (de)
CN (1) CN1231474C (de)
AP (1) AP2001002358A0 (de)
AR (1) AR031512A1 (de)
AT (1) ATE340786T1 (de)
AU (2) AU1420402A (de)
BG (1) BG107752A (de)
BR (1) BR0115621A (de)
CA (1) CA2430065C (de)
CR (1) CR6963A (de)
CY (1) CY1106240T1 (de)
CZ (1) CZ20031315A3 (de)
DE (1) DE60123461T2 (de)
DK (1) DK1337521T3 (de)
DO (1) DOP2001000288A (de)
EA (1) EA005859B1 (de)
EC (1) ECSP034628A (de)
EE (1) EE200300247A (de)
ES (1) ES2271086T3 (de)
GE (1) GEP20053652B (de)
GT (1) GT200100237A (de)
HN (1) HN2001000268A (de)
HR (1) HRP20030408A2 (de)
HU (1) HUP0302553A3 (de)
IL (1) IL155371A0 (de)
IS (1) IS6788A (de)
MA (1) MA26960A1 (de)
MX (1) MXPA03004714A (de)
MY (1) MY136686A (de)
NO (1) NO325187B1 (de)
NZ (1) NZ525788A (de)
OA (1) OA12532A (de)
PA (1) PA8533801A1 (de)
PE (1) PE20020591A1 (de)
PL (1) PL362079A1 (de)
PT (1) PT1337521E (de)
SI (1) SI1337521T1 (de)
SK (1) SK5862003A3 (de)
SV (1) SV2002000748A (de)
TN (1) TNSN01167A1 (de)
TW (1) TWI287542B (de)
UA (1) UA74221C2 (de)
UY (1) UY27039A1 (de)
WO (1) WO2002044158A1 (de)
YU (1) YU36403A (de)
ZA (1) ZA200303341B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP1527071A1 (de) * 2002-07-25 2005-05-04 Pfizer Products Inc. Isothiazolderivate und ihre verwendung zur krebsbekämpfung
CA2495962A1 (en) * 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
ATE517622T1 (de) * 2003-10-27 2011-08-15 Merck Sharp & Dohme Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
EP1778669A2 (de) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase-inhibitoren
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2044043B2 (de) 2006-06-16 2021-03-03 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin hydrobromid als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a-aktivität zur behandlung kognitiver störungen
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
PL2968650T3 (pl) * 2013-03-14 2019-05-31 Panoptica Inc Preparaty do oczu do dostarczania leku do tylnego fragmentu oka
ES2863601T3 (es) * 2014-09-17 2021-10-11 Panoptica Inc Formulaciones oculares para administración de fármacos y protección del segmento anterior del ojo
AU2023416218A1 (en) * 2022-12-28 2025-07-10 Beyang Therapeutics Co., Ltd. Protein tyrosine kinase inhibitor and medical use thereof
WO2026002133A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂的盐型
WO2026002142A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂的半琥珀酸盐晶型
WO2026002126A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其眼用制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
HRP20030408A2 (en) 2003-08-31
EP1337521B1 (de) 2006-09-27
CR6963A (es) 2003-11-25
DK1337521T3 (da) 2007-01-29
DOP2001000288A (es) 2002-12-15
TNSN01167A1 (fr) 2005-11-10
JP2008056692A (ja) 2008-03-13
EP1337521A1 (de) 2003-08-27
IL155371A0 (en) 2003-11-23
MXPA03004714A (es) 2003-08-19
AP2001002358A0 (en) 2001-12-31
CY1106240T1 (el) 2011-06-08
SI1337521T1 (sl) 2006-12-31
KR20030059275A (ko) 2003-07-07
SV2002000748A (es) 2002-12-02
DE60123461D1 (de) 2006-11-09
UY27039A1 (es) 2002-07-31
PA8533801A1 (es) 2002-10-31
AU1420402A (en) 2002-06-11
EA005859B1 (ru) 2005-06-30
NO20032388L (no) 2003-07-18
OA12532A (en) 2006-06-02
NZ525788A (en) 2004-11-26
JP4971946B2 (ja) 2012-07-11
HK1059085A1 (en) 2004-06-18
TWI287542B (en) 2007-10-01
CN1476439A (zh) 2004-02-18
ZA200303341B (en) 2004-04-30
EA200300424A1 (ru) 2003-10-30
CA2430065C (en) 2008-05-20
PE20020591A1 (es) 2002-07-06
MY136686A (en) 2008-11-28
JP2004514714A (ja) 2004-05-20
DE60123461T2 (de) 2007-02-15
PT1337521E (pt) 2006-12-29
CZ20031315A3 (cs) 2004-04-14
US20020151573A1 (en) 2002-10-17
US6831091B2 (en) 2004-12-14
CA2430065A1 (en) 2002-06-06
EE200300247A (et) 2003-10-15
HUP0302553A2 (hu) 2003-11-28
HN2001000268A (es) 2002-01-30
KR20050116401A (ko) 2005-12-12
CN1231474C (zh) 2005-12-14
WO2002044158A1 (en) 2002-06-06
IS6788A (is) 2003-04-14
ES2271086T3 (es) 2007-04-16
GEP20053652B (en) 2005-11-10
ECSP034628A (es) 2003-07-25
PL362079A1 (en) 2004-10-18
YU36403A (sh) 2006-08-17
GT200100237A (es) 2002-07-03
UA74221C2 (uk) 2005-11-15
AU2002214204B2 (en) 2007-05-24
NO325187B1 (no) 2008-02-11
AR031512A1 (es) 2003-09-24
BR0115621A (pt) 2003-09-02
MA26960A1 (fr) 2004-12-20
BG107752A (bg) 2004-01-30
HUP0302553A3 (en) 2009-03-30
NO20032388D0 (no) 2003-05-27
SK5862003A3 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
ATE340786T1 (de) Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel
DE60123210D1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
DE60106599D1 (de) Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
EP1581622A4 (de) Remodellierung und glycokonjugation von erythropoetin
ATE494338T1 (de) Verwendung eines moo3-korrosionsinhibitors
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE69926800D1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE60127233D1 (de) 4-aminopicolinate und ihre verwendung als herbizide
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE374191T1 (de) Urea derivate als integrin alpha 4 antagonisten
ATE461171T1 (de) Neue mandelsäurederivate und deren verwendung als thrombininhibitoren
ATE357432T1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
ATE321023T1 (de) 3-phenoxy-1-phenyl acetylenderivate und ihre verwendung als herbizide
DE50110553D1 (de) Verwendung herbizider Mittel
ATE290530T1 (de) Kristalline hydrate von anilid-derivaten als funigizide und insektizide
AR028281A1 (es) Derivados de 2-(arilalquilamino) pirimidona y derivados de 2-(heteroaroarilalquilamino) pirimidona
DE60122181D1 (de) Regelung eines turboladers
ATE308323T1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
PT1446399E (pt) Derivados de piperazina tendo actividade antagonista de sst1
DE60102151D1 (de) Neue thiochromanderivate und ihre verwendung als thrombininhibitoren
ATE316087T1 (de) Isothiazol-derivate und ihre verwendung als schädlingsbekämpfungsmittel
DE50004274D1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one und ihre verwendung als lipase-hemmer
DE60217870D1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
DE50208357D1 (de) Ansteuerung eines leuchtrings

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1337521

Country of ref document: EP

REN Ceased due to non-payment of the annual fee